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Abstract
Introduction: It has been suggested that adipose tissue hormones are involved in the mechanism of action of angiotensin-converting
enzyme (ACE) inhibitors. Very little is known as to whether the action on resistin contributes to the clinical effectiveness associated with
the use of these agents.
Material and methods: The aim of this study was to compare the effects of plasma- and tissue-type ACE inhibitors (enalapril and perin-
dopril) on plasma resistin content in coronary artery disease (CAD) individuals without arterial hypertension. The samples used in our
analysis were obtained at baseline, and again after 30 and 90 days of treatment, from 22 patients receiving enalapril (20 mg/d), 24 receiving
perindopril (4 mg/d), 20 receiving no angiotensin-converting enzyme inhibitors, and 20 healthy subjects. Each group consisted of patients
sensitive and resistant to insulin.
Results: Plasma resistin content was higher in normotensive CAD patients, particularly in the subgroup with reduced insulin sensitivity,
than in the control group. Both ACE inhibitors produced a weak effect on blood pressure. Perindopril treatment reduced resistin levels,
while enalapril only tended to decrease its content. The effect of perindopril was stronger in insulin-resistant than in insulin-sensitive
subjects.
Conclusions: Our results demonstrate the superiority of perindopril over enalapril in reducing plasma resistin levels, particularly in
insulin-resistant subjects. They justify the choice of a tissue-type ACE inhibitor in normotensive CAD individuals, requiring administra-
tion of this group of agents. (Pol J Endocrinol 2010; 61 (6): 683–690)
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Streszczenie
Wstęp: Hormony tkanki tłuszczowej wydają się odgrywać istotną rolę w mechanizmie działania inhibitorów enzymu konwertującego
angiotensynę (ACE, angiotensin-converting enzyme). Bardzo niewiele wiadomo na temat związku pomiędzy wpływem na wydzielanie
rezystyny a efektywnością kliniczną, związaną ze stosowaniem tej grupy leków.
Materiał i metody: Celem badania było porównanie wpływu osoczowego (enalapril) i tkankowego (perindopril) inhibitora ACE na stęże-
nie w osoczu rezystyny u chorych z chorobą wieńcową i prawidłowym ciśnieniem tętniczym krwi. Próbki wykorzystywane w analizie
pobierano przed oraz po 30 i 90 dniach leczenia od 22 osób otrzymujących enalapril (20 mg/dobę), 24 osób leczonych perindoprilem (4 mg/
/dobę), 20 chorych nieotrzymujących żadnego inhibitora ACE oraz od 20 zdrowych ochotników. Każda grupa obejmowała podgrupę osób
z zachowaną wrażliwością na insulinę oraz podgrupę chorych z insulinoopornością.
Wyniki: W porównaniu z grupą zdrowych ochotników, osoby z chorobą wieńcową wykazywały wyższe stężenia rezystyny. Oba inhibi-
tory ACE powodowały jedynie nieznaczne zmiany wartości ciśnienia tętniczego. Podawanie perindoprilu doprowadzało do spadku rezy-
stynemii, podczas gdy obniżenie stężenia rezystyny w osoczu osób stosujących enalapril nie osiągało poziomu znamienności statystycz-
nej. Wpływ perindoprilu na rezystynemię był wyraźniej wyrażony u osób z insulinoopornością.
Wnioski: Wyniki badania wskazują na silniejszy wpływ perindoprilu od enalaprilu na stężenie rezystyny w osoczu, zwłaszcza
u osób z insulinoopornością. Uzyskane wyniki uzasadniają wybór tkankowego inhibitora ACE u osób z chorobą niedokrwienną, u któ-
rych istnieją wskazania do zastosowania tej grupy leków. (Endokrynol Pol 2010; 61 (6): 683–690)
Słowa kluczowe: perindopril, enalapril, choroba wieńcowa, insulinooporność, rezystyna
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Introduction
Adipose tissue is a highly active metabolic and endo-
crine organ secreting a range of bioactive peptides with
both local and distant actions [1–3]. Some of these fac-
tors, known as ‘adipokines’ or ‘adipose tissue hor-
mones’, are specific fat-related hormones that are in-
volved in regulating energy homeostasis, carbohydrate
and lipid metabolism, and the function of the cardio-
vascular system [1-3]. In recent years there have been
arguments that adipose tissue products are involved in
the mechanism of action of angiotensin-converting en-
zyme (ACE) inhibitors. Administration of these agents
reduced plasma leptin content in hypertensive subjects
(ramipril) [4], and subjects with concomitant hyperten-
sion and obesity (enalapril) [5]. Moreover, ACE inhibi-
tors increased plasma adiponectin levels in hyperten-
sives (cilazapril, ramipril) [4, 6], type 2 diabetes patients
(ramipril) [7], and hypertensive patients with concomi-
tant metabolic syndrome (ramipril) [8]. Because some
other studies [9–12] did not support these results, it is
possible that other adipokines may be more important
targets for ACE inhibitors than leptin and adiponectin.
Resistin is a member of the cysteine-rich proteins
called ‘resistin-like molecules’ (RELM) or ‘found in in-
flammatory zone’ (FIZZ) [13]. Interestingly, there are
marked interspecies differences in the source of pro-
duction and structure of this protein, suggested to be
a mediator of hepatic insulin resistance [13]. In mice,
resistin is produced mainly by adipocytes of white adi-
pose tissue [14]. In humans, adipocytes produce only
small amounts of this protein [15], whereas relatively
high levels of resistin mRNA levels are detected in stro-
mal vascular cells of adipose tissue and in circulating
mononuclear cells [16, 17]. Interestingly, mouse and
human resistin share only about 64% sequence homol-
ogy at the mRNA level and only 59% identity at the
amino acid structure [18]. Taking into consideration the
above-described differences in localisation and in ami-
no acid structure, it is understandable that the physio-
logical function of resistin may in part differ between
humans and rodents [19]. Some [20, 21], but not all [22,
23], authors have observed that plasma resistin levels
positively correlate with obesity and other components
of the metabolic syndrome. Moreover, high plasma re-
sistin levels correlate with impaired renal function in
patients with chronic kidney disease [24], with the se-
verity of inflammation in inflammatory bowel disease
[25], and with increased risk for cardiac events in pa-
tients with congestive heart failure [26].
Only one study thus far has determined the action
of any ACE inhibitor on resistin. Koh et al. [27] observed
a ramipril-induced decrease in plasma resistin levels,
although this effect was less pronounced than that of
amlodipine. Interestingly, a similar beneficial action on
resistinaemia was produced by angiotensin II receptor
blockers (telmisartan, irbesartan) in rosiglitazone-treat-
ed type 2 diabetic subjects with metabolic syndrome
[28]. Because the role of resistin in insulin sensitivity,
obesity, type 2 diabetes and cardiovascular disease in
humans still remains uncertain, in the present study
we determined the effect of two different ACE inhibi-
tors on plasma resistin levels in normotensive patients
with coronary artery disease (CAD). Moreover, we as-
sessed whether the presence of insulin resistance de-
termines the strength of ACE inhibitor action.
Material and methods
Subjects
We retrospectively analysed plasma samples obtained
from 66 normotensive patients with CAD included in
our previous study [29]. These subjects (40–69 years old)
diagnosed with CAD were enrolled in the study if they
had either clinical symptoms of this disorder despite
treatment with acetylsalicylic acid, a beta-blocker and
a statin, or a positive result of the exercise test (defined
as horizontal or downsloping ST-segment depression
of at least 1 mm at 80 ms after the J point). The exclu-
sion criteria of the original study were: 1) any form of
acute coronary syndrome or a previous history of acute
coronary syndrome; 2) chronic coronary artery disease
being an indication for coronarography; 3) other acute
ischaemic conditions (presently or in the past); 4) dia-
betes mellitus; 5) obesity (BMI > 30 kg/m2); 6) symp-
tomatic congestive heart failure; 7) any form of arterial
hypertension; 8) any acute and chronic inflammatory
processes; 9) impaired renal or hepatic function; 10)
malabsorption syndromes; 11) previous treatment with
ACE inhibitors or the existence of contraindications to
administration of ACE inhibitors; and 12) poor patient
compliance [29].
Study design
All individuals participating in the original study were
fully informed of the purpose and the possible risks and
provided written informed consent. The study was
performed according to the Declaration of Helsinki, and
the Ethics Committee of the Medical University of Sile-
sia approved its protocol. They were treated for 90 days
with either enalapril (20 mg daily) or perindopril (4 mg
daily), or they received no ACE inhibitor. No changes
in dosage during the entire study period were allowed.
The samples were collected before therapy started and
after 30 and 90 days of therapy. Systolic and diastolic
blood pressures were measured in a sitting posture,
determined during Korotkoff sounds 1 and 5, respec-
tively. The values used in analyses were the means of
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three measurements taken at intervals of at least five
minutes [29].
In the present study, we chose to analyse the plas-
ma samples of 22 subjects treated with enalapril and 24
patients treated with perindopril, as well as the sam-
ples obtained from 20 subjects receiving no ACE inhib-
itor (4 mg daily) and from 20 healthy individuals. On
the basis of the result of HOMA index, each treatment
group was divided into two subgroups, with ‘normal’
or ‘disturbed’ insulin sensitivity. Normal insulin sensi-
tivity was arbitrarily defined as HOMA index less than
2.0. If this value was exceeded, the patient was diag-
nosed as insulin-resistant.
Laboratory assays
The frozen plasma samples, stored at –70°C, were
thawed naturally at room temperature just before test-
ing. All assays were carried out in duplicate, and mean
values are presented.
Plasma glucose content was measured by a glucose
oxidase method (Beckman, Palo Alto, CA, USA). Plas-
ma lipids (total cholesterol, LDL-cholesterol, HDL-cho-
lesterol and triglycerides) were determined using
bioMerieux reagents (Marcy-l’Etoile, France). Lipid pro-
file was assayed by a colorimetric method (bioMerieux,
France). LDL levels were measured directly. Plasma glu-
cose levels were measured by a glucose oxidase meth-
od (Beckman, Palo Alto, CA, USA). Plasma insulin was
determined with a commercial radioimmunoassay kit
(Linco Research Inc, St Charles, MO, USA), that does
not cross-react with proinsulin. Homeostasis model as-
sessment (HOMA) index was calculated as the product
of the fasting plasma insulin level (mU/L) and the fast-
ing plasma glucose level (mg/dL), divided by 405. Re-
sistin levels were investigated as previously [30] using
commercially available ELISA kits (R&D Systems , Min-
neapolis, MN, USA). Intra- and interassay coefficients
of variation of all measurements were less than 5% [30].
Statistical analysis
Results are shown as means ± standard deviation.
Treatment groups were compared using one-way ANO-
VA followed by Bonferroni’s post hoc analysis (arterial
pressure, lipid profile and plasma glucose) or using the
Kruskall-Wallis test followed by the Mann-Whitney U
test (HOMA and resistin). Student’s paired t test (arte-
rial pressure, lipid profile and plasma glucose) or the
Wilcoxon test (HOMA and resistin) were used to com-
pare differences between the means of variables within
the same treatment group. For categorical variables c2
test was used. Correlations were determined with Ken-
dall’s tau test. P values less than 0.05 were regarded as
statistically significant. Statistical analysis was per-
formed using the GraphPad Prism 2.01 software for
Windows (GPA-26576-117).
Results
Baseline characteristics
The groups were comparable in respect of demograph-
ics, medical background, clinical characteristics and safety
measurements. Compared to healthy subjects, normo-
tensive patients with CAD had increased plasma levels
of resistin (p < 0.001). According to our assumptions,
the HOMA index was higher in insulin-resistant than
in insulin-sensitive subjects (p < 0.001). Insulin-resistant
CAD patients, when assessed together, had higher resis-
tin levels than insulin-sensitive CAD subjects (p < 0.05)
(Table I).
Effect of ACE inhibitors on blood pressure,
insulin sensitivity and plasma lipids
(data not shown)
In healthy subjects, and in CAD subjects not receiving
any ACE inhibitor, blood pressure, the HOMA index and
lipid profile remained unaltered throughout the study.
ACE inhibitors only insignificantly reduced systolic
and diastolic blood pressure. The decrease was by
2.4/1.4 and 2.9/1.6 mm Hg (perindopril) and by 3.4/1.9
and 3.3/2.0 mmHg (enalapril), respectively, after 30 and
90 days of treatment.
Perindopril tended to reduce the HOMA index by
19.4% (p = 0.092) after 30 days of administration, and
by 25.0% (p < 0.05) at the end of the study. Adminis-
tered for 30 days, enalapril produced no effect on the
HOMA index, but tended to reduce this parameter by
20.8% (p = 0.078) when given for 90 days.
Neither perindopril nor enalapril affected plasma
lipids.
Effect of perindopril and enalapril on plasma
resistin levels
Thirty- and 90-day treatment with perindopril reduced
plasma resistin levels by, respectively, 25.8% (p < 0.05)
and 49.2% (p < 0.001). Post-treatment plasma leptin did
not differ from that observed in control subjects. The
effect of perindopril was stronger at the end of the study
than after 30 days of therapy (p < 0.01).
Enalapril only insignificantly reduced resistinaemia,
by 20.3% (p = 0.083) and by 22.7% (p = 0.056), after
30 and 90 days of treatment, respectively. At the end of
the study, plasma resistin remained higher than in
healthy subjects (p < 0.01).
In CAD subjects not receiving any ACE inhibitor,
and in healthy subjects, plasma resistin levels remained
at similar levels throughout the study (Fig. 1).
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The analysis of subgroups (Fig. 2)
Insulin-sensitive patients
In patients with normal value of the HOMA index, per-
indopril treatment insignificantly reduced plasma re-
sistin (–22.8%, p = 0.062) after 30 days of administra-
tion and decreased it significantly by 33.3% (p < 0.01)
at the end of the study. In this subgroup of subjects, no
effect was produced by enalapril.
Insulin-resistant patients
Perindopril administered to insulin-resistant subjects
reduced resistinaemia by 28.8% (p < 0.01) and by 58.9%
(p < 0.001) after 30 and 90 days of treatment, respec-
Table I. Baseline characteristics of patients
Tabela I. Wyjściowa charakterystyka pacjentów
Healthy Patients not treated Enalapril-treated Perindopril-treated
subjects  with ACE inhibitor  group  group
Number of patients 20 20 (9, 11) 22 (10, 12) 24 (11, 13)
Age (years) 50.7 ± 6.4 53.1 ± 6.8 52.9 ± 6.4 49.2 ± 5.0
(53.5 ± 7.0, (52.4 ± 6.7, (48.2 ± 5.8,
52.8 ± 7.1)  53.3 ± 6.5)   50.1 ± 5.2)
Females 25.0 25.0 (22.2, 27.3) 22.7 (20.0, 25.0) 20.8 (18.2, 23.1)
BMI [kg/m2] 26.4 ± 2.9 26.5 ± 2.2 27.3 ± 2.5 26.8 ± 2.4
(26.8 ± 2.9, (27.1 ± 2.6, (26.3 ± 2.9,
26.3 ± 2.3)   27.5 ± 2.2)   27.2 ± 2.5)
Smokers (%) 20.0 20.0 (22.2, 18.2) 18.2 (20.0, 12.5) 16.7 (18.2, 15.4)
Systolic blood pressure 122.1 ± 6.0 124.6 ± 7.0 125.5 ± 8.2 125.8 ± 7.1
[mm Hg] (122.3 ± 8.3, (121.6 ± 8.8, (125.0 ± 9.0,
126.5 ± 7.8)   128.8 ± 8.6)   126.5 ± 7.4)
Diastolic blood pressure 78.3 ± 6.4 77.9 ± 7.5 79.6 ± 7.1 80.0 ± 6.2
[mm Hg] (77.0 ± 8.2, (80.2 ± 8.5, (78.7 ± 7.3,
78.6 ± 8.0)   79.1 ± 6.9)   81.1 ± 7.0)
Medications
Statins (%) 0 90.0*** (88.9***, 90.9***) 90.9*** (90.0***, 91.7***) 91.7*** (90.9***, 92.3***)
Acetylsalicylic acid (%) 0 85.0*** (88.9***, 81.2***) 90.9*** (90.0***, 91.7***) 91.7*** (100.0***, 84.6***)
Beta-blockers (%) 0 90.0*** (100.0***, 81.2***) 86.4*** (90.0***, 83.3***) 91.7*** (90.9***, 92.3***)
Total cholesterol [mg/dL] 167.1 ± 9.6 215.3 ± 28.3 228.2 ± 38.2 223.0 ± 23.1
(212.1 ± 30.1, (218.1 ± 42.4, (225.2 ± 25.2,
217.9 ± 32.0)   236.6 ± 40.0)   221.1 ± 24.0)
LDL-cholesterol [mg/dL] 91.0 ± 6.0 150.4 ± 12.1 156.4 ± 27.5 142.5 ± 12.3
(149.8 ± 14.0, (148.4 ± 28.5, (135.1 ± 25.2,
150.9 ± 14.1)  163.1 ± 29.8)   148.8 ± 12.3)
HDL-cholesterol [mg/dL] 51.5 ± 3.7 46.6 ± 5.0 46.2 ± 7.9 47.1 ± 4.8
(51.4 ± 5.6, (52.1 ± 6.2, (53.2 ± 5.7,
42.7 ± 5.1)   41.3 ± 5.9)   42.0 ± 5.6)
Triglycerides [mg/dL] 116.5 ± 23.5 143.5 ± 14.2 149.3 ± 59.3 143.2 ± 46.5
(124.0 ± 34.9, (121.9 ± 48.0, (121.9 ± 39.2,
159.5 ± 36.0)   172.1 ± 63.2) 161.2 ± 50.4)
Glycaemia [mg/dL] 88.0 ± 5.1 90.8 ± 5.2 89.5 ± 9.0 91.2 ± 8.0
(84.4 ± 5.6, (82.7 ± 4.2, (84.1 ± 8.2,
96.0 ± 5.4)   95.2 ± 5.3) 97.2 ± 8.4)
HOMA index 1.3 ± 0.2 3.7 ± 0.5** 3.6 ± 0.5** 3.8 ± 0.5**
(1.4 ± 0.2, (1.1 ± 0.2, (1.3 ± 0.2,
5.5 ± 0.3***###)   5.7 ± 0.2***###)   6.0 ± 0.4***###)
Resistin [ng/mL] 3.5 ± 0.8 6.2 ± 1.0 ***# 6.4 ± 1.1*** 6.6 ± 1.3***
(5.6 ± 1.1, (5.8 ± 0.8, (5.7 ± 1.0,
6.7 ± 1.0***1)  6.9 ± 1.3***1) 7.3 ± 0.8***1)
The values in parentheses represent the baseline data in subgroups with normal and reduced insulin sensitivity, respectively.
Each value represents the mean ± SD. **P < 0.01, ***P < 0.001 v. healthy subjects, ###P < 0.001 v. insulin-sensitive subjects in the same treatment
group. 1statistically different (P < 0.05) v. subjects with normal insulin sensitivity when all insulin-sensitive (n = 30) and all insulin-resistant (n = 36)
subjects were compared to one another
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Figure 2. The impact of angiotensin-converting enzyme inhibitors on plasma resistin levels in insulin-sensitive and insulin-resistant
subjects with isolated coronary artery disease. Data represents the mean ± SD. *p < 0.05 v. insulin-sensitive patients, #P < 0.05,
##P < 0.01, ###P < 0.001 v. pretreatment values, $$$P < 0.001 the effect stronger than after 30 days of treatment, ^^^P < 0.001 the
effect of perindopril stronger than that of enalapril at the end of the study
Rycina 2. Wpływ inhibitorów enzymu konwertującego angiotensynę na stężenie rezystyny w osoczu pacjentów z chorobą niedokrwienną
serca i prawidłową oraz upośledzoną wrażliwością na insulinę. Wyniki przedstawiają średnią ± odchylenie standardowe. *p < 0.05
osoby z prawidłową wrażliwością na insulinę; #p < 0.05, ##P < 0.01, ###p < 0.001 v. wartość przed leczeniem; $$$p < 0.001 wpływ leku
silniejszy niż po 30 dniach leczenia; ^^^p < 0.001 pod koniec terapii wpływ perindoprilu silniejszy od enalaprilu
Figure 1. Effect of angiotensin-converting enzyme inhibitors on plasma resistin levels in normotensive patients with coronary artery
disease. Data represents the mean ± SD. **p < 0.01, ***p < 0.001 v. healthy subjects, #P < 0.05, ###P < 0.001 v. pretreatment
values, $$P < 0.01 the effect stronger than after 30 days of treatment, ^^P < 0.01 the effect of perindopril stronger than that of enalapril
at the end of the study
Rycina 1. Wpływ inhibitorów ACE na stężenie rezystyny w osoczu pacjentów z chorobą niedokrwienną serca i prawidłową wartością
ciśnienia tętniczego. Wyniki przedstawiają średnią ± odchylenie standardowe. **p < 0.01, ***p < 0.001 v. zdrowi ochotnicy; #p < 0.05,
###p < 0.001 v. wartość przed leczeniem; $$p < 0.01 wpływ leku silniejszy niż po 30 dniach leczenia; ^^p < 0.01 pod koniec terapii
wpływ perindoprilu silniejszy od enalaprilu
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tively. After 30 days of administration, enalapril tend-
ed to reduce resistin by 23.4% (p = 0.053), while at the
end of the study this decrease was by 27.5% (p < 0.05).
Comparisons between the groups (Fig. 1 and 2)
Perindopril was superior to enalapril in decreasing plas-
ma resistin levels in the whole population of normo-
tensive subjects with CAD (p < 0.01) and in insulin-
resistant subjects (p < 0.001). ACE inhibitor action on
plasma resistin was more pronounced in insulin-resis-
tant than in insulin-sensitive patients.
Correlations
At baseline, plasma resistin levels correlated with the
HOMA index (r = 0.41, p < 0.01), but not with lipid
profile, and systolic and diastolic blood pressure. There
was a correlation between ACE inhibitor action on plas-
ma resistin and its effect on the HOMA index (r = 0.47,
p < 0.01 for perindopril; r = 0.38, p < 0.05 for enala-
pril). Perindopril and enalapril action on resistinaemia
did not correlate with its effect on plasma lipid or arte-
rial pressure.
Discussion
Our study found that the action of ACE inhibitors on
plasma resistin is determined by pharmacokinetic and
pharmacodynamic properties of these agents as well as
by baseline insulin sensitivity. Normotensive CAD pa-
tients with abnormal tissue response to insulin are prob-
ably better candidates for therapy with ACE inhibitors
than those with normal insulin sensitivity.
Our study revealed that individuals with CAD ex-
hibited higher plasma resistin levels than their healthy
counterparts. This finding is in line with some previous
data showing that increased resistinaemia is related to
increased cardiovascular risk [31, 32]. It is worth men-
tioning that plasma resistin slightly differed between
insulin-resistant and insulin-sensitive subjects. As vari-
ous responses to insulin were the only differences be-
tween the two subgroups of CAD patients, higher re-
sistinaemia in insulin-resistant persons may suggest that
the risk of the progression and development of compli-
cations is increased if CAD is accompanied by even small
disturbances in insulin receptor action. Because in per-
sons with overt diabetes insulin resistance is usually
more severe than in non-diabetic individuals [33, 34],
patients with concomitant CAD and type 2 diabetes
probably have even higher plasma resistin content than
the insulin-resistant participants in our study. If this is
the case, enhanced production of resistin may contrib-
ute to the markedly increased risk of vascular compli-
cations, which is characteristic of CAD patients with type
2 diabetes [35].
Our study has shown that perindopril lowered plas-
ma resistin levels, while the effect of enalapril was much
more moderate. This finding cannot be regarded as
unexpected, as it is in line with the results of the initial
study [29], which showed the superiority of perindopril
over enalapril in CAD patients when it comes to pro-
ducing anti-inflammatory, anti-oxidant, anti-thrombotic
and profibrinolytic effects. It is also in agreement with
our recent, yet unpublished results [Krysiak et al. — sub-
mitted to ”Polish Journal of Endocrinology”], which
have shown a stronger impact of perindopril than enal-
april on plasma leptin and adiponectin content in indi-
viduals with isolated CAD. The latter study, together
with the present one, clearly indicate that perindopril,
and possibly also other tissue-type ACE inhibitors, pro-
duce a quick, beneficial and multidirectional effect on
the endocrine function of human adipose tissue. Tak-
ing into account the more pronounced anti-inflamma-
tory, anti-oxidant and haemostatic actions of perin-
dopril, as well as a stronger impact on peptides released
by adipose tissue despite similar metabolic actions of
both assessed ACE inhibitors, its seems that CAD pa-
tients requiring an ACE inhibitor should be treated with
a tissue-type rather than with a plasma-type agent. Sim-
ilarly as in the case of monocyte chemoattractant pro-
tein-1, interleukin-10, C-reactive protein, fibrinogen,
plasminogen activator inhibitor-1 [29], leptin and adi-
ponectin [Krysiak et al. — submitted to ”Polish Journal
of Endocrinology”], the resistin-lowering action of per-
indopril was observed despite treatment of patients with
acetylsalicylic acid, a statin as well as with a b-blocker.
The presence of multidirectional beneficial pleiotro-
pic actions of perindopril in this population of patients
supports their use in subjects with clinically or elec-
trocardiographically-confirmed CAD, who experience
the symptoms of this disorder despite treatment with
established cardioprotective agents. These pluripoten-
tial hypotensive-independent effects may be some of
the mechanisms due to which tissue ACE inhibitors
are effective in the prevention of cardiovascular dis-
orders [36, 37].
Probably the most important finding of our study is
that the strength of ACE inhibitor action depended on the
level of tissue insulin sensitivity. Perindopril, and to a less
extent also enalapril, more effectively reduced plasma re-
sistin in subjects with disturbed sensitivity to insulin than
in those with normal tissue response to this hormone.
To the best of our knowledge, no previous study
has demonstrated that the effect of any hypotensive
agent on adipokines is determined by the baseline tis-
sue sensitivity to insulin. However, it is clinically con-
firmed that ACE inhibitors or angiotensin II receptor
blockers are effective in diabetes management, and
therefore in order to prevent its complications they
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should be administered to all type 2 diabetic patients,
even to those without hypertension or systolic dysfunc-
tion of the left ventricle [38, 39]. The results of our study
seem to broaden these indications even to subjects with
milder abnormalities in insulin action. Because in this
group of patients the superiority of perindopril over
enalapril was particularly marked, in normotensive in-
sulin-resistant CAD patients, tissue-type ACE inhibitors
should be strongly preferred.
Although an insignificant decrease in plasma resis-
tin in perindopril-treated subjects was observed after
only 30 days of therapy, this effect was stronger at the
end of the study. This suggests that perindopril should
be administered for at least several months to exhibit
its maximal pleiotropic effect on the hormonal function
of adipose tissue, and justifies the long-term adminis-
tration of these agents.
It should be mentioned that both ACE inhibitors re-
sulted in only small changes in blood pressure. This fact,
and good tolerance of perindopril and enalapril in our
normotensive population, indicate that the presence of
normal blood pressure cannot disqualify CAD patients
from administration of an ACE inhibitor, if such a treat-
ment is clinically justifiable.
Our study is not free from limitations. The diagno-
sis of CAD was established only on the basis of indirect
criteria (no coronary angiography was performed). It
cannot be excluded that some individuals were misdi-
agnosed with CAD, while some healthy subjects had
asymptomatic atherosclerotic lesions in their coronary
vessels. The number of patients in each group and sub-
group was relatively small. Therefore, it is not unlikely
that the effect of enalapril on resistinaemia is stronger
than observed by us. It may reach the level of signifi-
cance, provided that more participants are enrolled in
the study. Nevertheless, even in such a case, the effect
on plasma resistin is less pronounced than that of per-
indopril. Moreover, in our study the term ‘insulin-re-
sistant’ encompasses subjects with impaired fasting glu-
cose, impaired glucose tolerance and some with nor-
mal glucose tolerance (only subjects with diabetes were
excluded). It is possible that ACE inhibitor action on
resistin may differ between the three subgroups. Final-
ly, as we assessed only one adipokine, the question of
whether the action of ACE inhibitors on other adipose
tissue products also depends on insulin sensitivity re-
quires further investigation.
Conclusions
Our study shows that the presence of isolated CAD is
associated with higher plasma levels of resistin. Perin-
dopril exhibits a stronger resistin-lowering action than
enalapril, and this effect is particularly pronounced in
insulin-resistant patients. Our results indicate that tis-
sue-type ACE inhibitors probably bring more metabol-
ic and hormonal benefits to normotensive CAD subjects
than plasma-type ones, and therefore should be pre-
ferred in this group of patients.
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